Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Change in Receivables (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Change in Receivables for 12 consecutive years, with $8.3 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 114.8% to $8.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$93.6 million through Dec 2025, up 37.36% year-over-year, with the annual reading at -$93.6 million for FY2025, 37.36% up from the prior year.
  • Change in Receivables hit $8.3 million in Q4 2025 for Coherus Oncology, up from $4.3 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $75.3 million in Q3 2023 to a low of -$76.6 million in Q2 2024.
  • Historically, Change in Receivables has averaged -$7.0 million across 5 years, with a median of -$6.9 million in 2022.
  • Biggest five-year swings in Change in Receivables: surged 3084.96% in 2023 and later tumbled 493.2% in 2025.
  • Year by year, Change in Receivables stood at -$13.3 million in 2021, then surged by 240.91% to $18.8 million in 2022, then soared by 134.38% to $44.1 million in 2023, then tumbled by 227.85% to -$56.3 million in 2024, then skyrocketed by 114.8% to $8.3 million in 2025.
  • Business Quant data shows Change in Receivables for CHRS at $8.3 million in Q4 2025, $4.3 million in Q3 2025, and -$55.3 million in Q2 2025.